La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Hyundai Bioscience Bilan de santé

Santé financière contrôle des critères 4/6

Hyundai Bioscience possède un total de capitaux propres de ₩60.5B et une dette totale de ₩35.8B, ce qui porte son ratio d'endettement à 59.1%. Son actif total et son passif total sont ₩105.7B et de ₩45.2B.

Informations clés

59.1%

Ratio d'endettement

₩35.77b

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	₩24.93b
Fonds propres	₩60.53b
Total du passif	₩45.17b
Total des actifs	₩105.70b

Mises à jour récentes de la santé financière

Is Hyundai Bioscience (KOSDAQ:048410) Using Too Much Debt?

Feb 07

Recent updates

The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About

Mar 14

Is Hyundai Bioscience (KOSDAQ:048410) Using Too Much Debt?

Feb 07

Imagine Holding Hyundai Bioscience (KOSDAQ:048410) Shares While The Price Zoomed 439% Higher

Jan 03

The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About

Nov 29

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de A048410 ( ₩30.9B ) ne couvrent pas ses passifs à court terme ( ₩42.7B ).

Passif à long terme: Les actifs à court terme de A048410 ( ₩30.9B ) dépassent ses passifs à long terme ( ₩2.5B ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de A048410 ( 17.9% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de A048410 est passé de 36.1% à 59.1% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: A048410 dispose d'une piste de trésorerie suffisante pour plus de 3 ans sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: A048410 dispose d'une marge de trésorerie suffisante pour plus de 3 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 25.6 % chaque année

Hyundai Bioscience Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

Is Hyundai Bioscience (KOSDAQ:048410) Using Too Much Debt?

Recent updates

Hyundai Bioscience USA Signs an MOU with the University of California San Diego to Conduct an Investigator-Initiated Trial to Evaluate the Efficacy of Xafty

New major risk - Financial data availability

Hyundai Bioscience Co., Ltd. to Conduct Phase 3 Clinical Trial for High-Risk Group of COVID-19 Patients with the Goal of Emergency Use Authorization

Hyundai Bioscience Co., Ltd. announced that it expects to receive KRW 3 billion in funding

Hyundai Bioscience Co., Ltd. (KOSDAQ:A048410), CnPharm Co., Ltd. and Yeonjin Kim completed the acquisition of 34.91% stake in ADM Korea Inc. (KOSDAQ:A187660) from Mobiis Co., Ltd. (KOSDAQ:A250060).

Hyundai Bioscience's Antiviral for Dengue Fever to Enter Clinical Trials in Brazil

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-Based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Hyundai Bioscience Announces Its Successful Result from A Preclinical Study of A Niclosamide-Based Oral Anticancer Drug to Treat Triple-Negative Breast Cancer

Hyundai Bioscience Co., Ltd. (KOSDAQ:A048410), CnPharm Co., Ltd. and Yeonjin Kim agreed to acquire 32.47% stake in ADM Korea Inc. (KOSDAQ:A187660) from Mobiis Co., Ltd. (KOSDAQ:A250060) for KRW 31 billion.

Full year 2023 earnings released: ₩365 loss per share (vs ₩402 loss in FY 2022)

New major risk - Share price stability

Vector Inc. (TSE:6058) completed the acquisition of additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd. (KOSDAQ:A048410)

Vector Inc. (TSE:6058) completed the acquisition of additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd. (KOSDAQ:A048410)

New major risk - Share price stability

Full year 2022 earnings released: ₩402 loss per share (vs ₩543 loss in FY 2021)

Less than half of directors are independent

Vector Inc. (TSE:6058) agreed to acquire additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd. (KOSDAQ:A048410) for KRW 13.7 billion.

Hyundai Bioscience to request a fast track processing for its monkeypox treatment drug with the FDA

Hyundai Bioscience Co., Ltd. Launches CP-COV03 Phase 2 Clinical Trials

Less than half of directors are independent

Hyundai Bioscience Co., Ltd. Announces Oral Antiviral Drug from Korea May Be A Problem Solver for Covid-19

The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About

New 90-day high: ₩37,100

Is Hyundai Bioscience (KOSDAQ:048410) Using Too Much Debt?

Imagine Holding Hyundai Bioscience (KOSDAQ:048410) Shares While The Price Zoomed 439% Higher

Hyundai Bioscience Develops Injection Drug for Potential Treatment of Severe Cases of COVID-19

New 90-day high: ₩13,650

The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About

New 90-day low: ₩10,150

New 90-day low: ₩10,800

Hyundai Bioscience Co., Ltd. announced that it has received KRW 32 billion in funding from a group of investors

Hyundai Bioscience Co., Ltd. announced that it expects to receive KRW 32 billion in funding from a group of investors

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines